| Insurance Carrier | Facility/Professional | Modifier | Low Price | Median Price | High Price |
|---|---|---|---|---|---|
Kaiser Permanente
| Professional | $393.93 | $836.00 | $1,824.00 | |
Lucent Health
| Facility | $1,269.68 | $4,104.64 | $4,254.29 | |
United
| Professional | $975.00 | $1,357.50 | $1,425.00 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
| Insurance Carrier | Facility/Professional | Modifier | Low Price | Median Price | High Price |
|---|---|---|---|---|---|
Kaiser Permanente
| Professional | $393.93 | $836.00 | $1,824.00 | |
Lucent Health
| Facility | $1,269.68 | $4,104.64 | $4,254.29 | |
United
| Professional | $975.00 | $1,357.50 | $1,425.00 |